Ironwood Sets Ambitious 2026 Guidance for LINZESS Net Sales and Profits—Adjusted EBITDA Projected to More Than Double
Market Chameleon (Mon, 5-Jan 10:36 AM)
Ironwood Pharmaceuticals Sharpens 2026 Guidance With Expected Surge in LINZESS Sales and EBITDA—What’s Powering This Confidence?
Market Chameleon (Fri, 2-Jan 9:53 AM)
Ironwood Targets Over $1.1 Billion in LINZESS Sales for 2026 Amid Strong Cash Position and R&D Progress
Market Chameleon (Fri, 2-Jan 7:59 AM)
